SanjeetSinghDadwalMDFACP

Transplant/Immunocompromised States

Chief, Division of Infectious Disease Clinical Professor Director, Antimicrobial Stewardship Infectious Disease Lead, Transplant Disease Team

Join to view full profile

Dr. Dadwal is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Dadwal's full profile

Already have an account?

Office
1500 Duarte Rd
Duarte, CA 91010
Phone+1 626-359-8111

Fax+1 626-218-5310

Summary

I am a board certified infectious disease physician with expertise in the management of opportunistic infections, especially in patients with hematologic malignancies, recipients of hematopoietic stem cell transplant and CAR-T cell recipients. My research interests span epidemiology of infectious complications (fungal, viral and bacterial) in immunocompromised host, infection control and antimicrobial stewardship in cancer patients.

Education & Training

SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1997 - 2000
All India Institute of Medical SciencesClass of 1997

Certifications & Licensure

CA State Medical License 2000 - 2025
UT State Medical License 2002 - 2006
CT State Medical License 1999 - 2002
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Examine the Effects of DAS181 in Immunocompromised Subjects With Lower Respiratory Tract Parainfluenza Infection on Supplemental Oxygen Start of enrollment: 2014 Mar 01
Completed
Phase 2
Letermovir (MK-8228) Versus Placebo in the Prevention of Clinically-Significant Cytomegalovirus (CMV) Infection in Adult, CMV-Seropositive Allogeneic Hematopoietic Stem Cell Transplant Recipients (MK-8228-001) Start of enrollment: 2014 Jun 06
Completed
Phase 3
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract Start of enrollment: 2015 Jan 23
Completed
Phase 2
Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus (RSV) Infection of the Lower Respiratory Tract Start of enrollment: 2015 Jan 31
Completed
Phase 2
Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir Start of enrollment: 2016 Dec 22
Completed
Phase 3
Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study Start of enrollment: 2019 May 23
Recruiting
Phase 3
Extension of Letermovir (LET) From Day 100 to Day 200 Post-transplant for the Prevention of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant (HSCT) Participants (MK-8228-040) Start of enrollment: 2019 Jun 21
Completed
Phase 3
Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy Start of enrollment: 2021 Jan 07
Terminated
Phase 1, Phase 2
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer Start of enrollment: 2021 Sep 27
Recruiting
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

7 citations
Efficacy of low-dose zoster prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation.
Kristen Mascarenhas, Jennifer Berano Teh, Kelly Peng, Heeyoung Kim, Andrew Sy
Bone Marrow Transplantation. 2020-08-01
69 citations
Clinical Evaluation of Safety and Immunogenicity of PADRE-Cytomegalovirus (CMV) and Tetanus-CMV Fusion Peptide Vaccines With or Without PF03512676 Adjuvant
Corinna La Rosa, Jeff Longmate, Simon F. Lacey, Teodora Kaltcheva, Rahul Sharan
The Journal of Infectious Diseases. 2012-04-15
53 citations
Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents.
Ibrahim Aldoss, Sanjeet Dadwal, Jianying Zhang, Bernard Tegtmeier, Matthew Mei
Blood Advances. 2019-12-10

Abstracts/Posters

Draft Genome Sequence of a Clinical Isolate of Fusarium Fujikuroi Isolated from a Male Patient with Acute Myeloid Leukemia
Sanjeet Dadwal, MD, mBio, Orlando, FL, 12/9/2019

Press Mentions

AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study in Oral Presentation at the 64th ASH Annual Meeting and ExpositionDecember 10th, 2022
Testing COVID-19 Treatments for Patients with Cancer: An Ongoing NeedFebruary 20th, 2021